Matthew S. Alexander

Matthew S. Alexander

Auto-generated profile, based on publicly available information

Matthew S. Alexander

Univ Iowa Hosp & Clin, Dept Surg, Iowa City, IA 52242 USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MAMatthew S. Alexander
Matthew S. Alexander
JWJustin G. Wilkes
Justin G. Wilkes
SSSamuel R. Schroeder
Samuel R. Schroeder
GBGarry Buettner
Garry Buettner
BWBrett Wagner
Brett Wagner
Joseph CullenJoseph Cullen
Joseph Cullen
Chemoradiation therapy is the mainstay for treatment of locally advanced, borderline resectable pancreatic cancer. Pharmacologic ascorbate (P-AscH−, i.e., intravenous infusions of ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations capable of selective cytotoxicity to tumor cells. In doses achievable in humans, P-AscH− decreases the viability and proliferative capacity of pancreatic cancer via a hydrogen peroxide (H2O2)-mediated mechanism. In this study, we demonstrate that P-AscH− radiosensitizes pancreatic cancer cells but inhibits radiation-induced damage to normal cells. Specifically, radiation-induced decreases in clonogenic survival and double-stranded DNA breaks in tumor cells, but not in normal cells, were enhanced by P-AscH−, while radiation-induced intestinal damage, collagen deposition, and oxidative stress were also reduced with P-AscH− in normal tissue. We also report on our first-in-human phase I trial that infused P-AscH− during the radiotherapy “beam on.” Specifically, treatment with P-AscH− increased median overall survival compared with our institutional average (21.7 vs. 12.7 months, P = 0.08) and the E4201 trial (21.7 vs. 11.1 months). Progression-free survival in P-AscH−–treated subjects was also greater than our institutional average (13.7 vs. 4.6 months, P < 0.05) and the E4201 trial (6.0 months). Results indicated that P-AscH− in combination with gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma is safe and well tolerated with suggestions of efficacy. Because of the potential effect size and minimal toxicity, our findings suggest that investigation of P-AscH− efficacy is warranted in a phase II clinical trial. Significance: These findings demonstrate that pharmacologic ascorbate enhances pancreatic tumor cell radiation cytotoxicity in addition to offering potential protection from radiation damage in normal surrounding tissue, making it an optimal agent for improving treatment of locally advanced pancreatic adenocarcinoma.

1 April 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
AGAdrienne R. Gibson
Adrienne R. Gibson
BOBrianne R. O'LEary
Brianne R. O'LEary
JDJuan Du
Juan Du
ESEhab Sarsour
Ehab Sarsour
AKAmanda L. Kalen
Amanda L. Kalen
Joseph CullenJoseph Cullen
Joseph Cullen
Pharmacologic ascorbate treatment (P-AscH−, high-dose, intravenous vitamin C) results in a transient short-term increase in the flux of hydrogen peroxide that is preferentially cytotoxic to cancer cells versus normal cells. This study examines whether an increase in hydrogen peroxide is sustained posttreatment and potential mechanisms involved in this process. Cellular bioenergetic profiling following treatment with P-AscH− was examined in tumorigenic and nontumorigenic cells. P-AscH− resulted in sustained increases in the rate of cellular oxygen consumption (OCR) and reactive oxygen species (ROS) in tumor cells, with no changes in nontumorigenic cells. Sources for this increase in ROS and OCR were DUOX 1 and 2, which are silenced in pancreatic ductal adenocarcinoma, but upregulated with P-AscH− treatment. An inducible catalase system, to test causality for the role of hydrogen peroxide, reversed the P-AscH−–induced increases in DUOX, whereas DUOX inhibition partially rescued P-AscH−–induced toxicity. In addition, DUOX was significantly downregulated in pancreatic cancer specimens compared with normal pancreas tissues. Together, these results suggest that P-AscH−–induced toxicity may be enhanced by late metabolic shifts in tumor cells, resulting in a feed-forward mechanism for generation of hydrogen peroxide and induction of metabolic stress through enhanced DUOX expression and rate of oxygen consumption. Significance: A high dose of vitamin C, in addition to delivering an acute exposure of H2O2 to tumor cells, activates DUOX in pancreatic cancer cells, which provide sustained production of H2O2.

19 August 2017 in Antioxidants
Verified
Journal Article
Open access
PDF file
JWJustin G. Wilkes
Justin G. Wilkes
MAMatthew S. Alexander
Matthew S. Alexander
Joseph CullenJoseph Cullen
Joseph Cullen
The incidence of pancreatic cancer is increasing as the population ages but treatment advancements continue to lag far behind. The majority of pancreatic cancer patients have a K-ras oncogene mutation causing a shift in the redox state of the cell, favoring malignant proliferation. This mutation is believed to lead to nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and superoxide overproduction, generating tumorigenic behavior. Superoxide dismutases (SODs) have been studied for their ability to manage the oxidative state of the cell by dismuting superoxide and inhibiting signals for pancreatic cancer growth. In particular, manganese superoxide dismutase has clearly shown importance in cell cycle regulation and has been found to be abnormally low in pancreatic cancer cells as well as the surrounding stromal tissue. Likewise, extracellular superoxide dismutase expression seems to favor suppression of pancreatic cancer growth. With an increased understanding of the redox behavior of pancreatic cancer and key regulators, new treatments are being developed with specific targets in mind. This review summarizes what is known about superoxide dismutases in pancreatic cancer and the most current treatment strategies to be advanced from this knowledge.

5 July 2018 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Open access
MAMatthew S. Alexander
Matthew S. Alexander
Joseph CullenJoseph Cullen
Joseph Cullen
(2018). Treating pancreatic cancer: more antioxidants more problems? Expert Review of Gastroenterology & Hepatology: Vol. 12, No. 9, pp. 849-851.

3 August 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CPCarolina Pinzon-Guzman
Carolina Pinzon-Guzman
SSSreedhara Sangadala
Sreedhara Sangadala
KRKatherine M. Riera
Katherine M. Riera
EPEvgenya Popova
Evgenya Popova
EMElizabeth Manning
Elizabeth Manning
JGJames R. Goldenring
James R. Goldenring
Esophageal atresia (EA/TEF) is a common congenital abnormality present in 1 of 4000 births. Here we show that atretic esophagi lack Noggin (NOG) expression, resulting in immature esophagus that contains respiratory glands. Moreover, when using mouse esophageal organoid units (EOUs) or tracheal organoid units (TOUs) as a model of foregut development and differentiation in vitro, NOG determines whether foregut progenitors differentiate toward esophageal or tracheal epithelium. These results indicate that NOG is a critical regulator of cell fate decisions between esophageal and pulmonary morphogenesis, and its lack of expression results in EA/TEF.

1 October 2017 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
MAMatthew S. Alexander
Matthew S. Alexander
BOBrianne R. O'Leary
Brianne R. O'Leary
AKAdrienne Klinger
Adrienne Klinger
BWBrett Wagner
Brett Wagner
Joseph CullenJoseph Cullen
Joseph Cullen